{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Oral+Solution&page=6", "query": { "intervention": "Placebo Oral Solution", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 618, "total_pages": 62, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Oral+Solution&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Oral+Solution&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T04:45:54.308Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05653349", "title": "Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Immune Thrombocytopenia (ITP)" ], "interventions": [ { "name": "Ianalumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Corticosteroids", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 226, "start_date": "2023-02-03", "completion_date": "2029-01-05", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-10-07T04:45:54.308Z", "location_count": 20, "location_summary": "Yuma, Arizona • Clovis, California • Fountain Valley, California + 16 more", "locations": [ { "city": "Yuma", "state": "Arizona" }, { "city": "Clovis", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Margate", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05653349" }, { "nct_id": "NCT02202226", "title": "Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Lu AF35700", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lundbeck A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 96, "start_date": "2013-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-03-06", "last_synced_at": "2026-10-07T04:45:54.308Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02202226" }, { "nct_id": "NCT00423813", "title": "A Safety and Efficacy Study of Xyrem® (Sodium Oxybate) to Treat Fibromyalgia.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fibromyalgia" ], "interventions": [ { "name": "placebo", "type": "DRUG" }, { "name": "Xyrem®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 573, "start_date": "2006-12", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2012-01-24", "last_synced_at": "2026-10-07T04:45:54.308Z", "location_count": 71, "location_summary": "Auburn, Alabama • Birmingham, Alabama • Montgomery, Alabama + 61 more", "locations": [ { "city": "Auburn", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00423813" }, { "nct_id": "NCT00734474", "title": "A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "LY2189265", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Placebo solution", "type": "DRUG" }, { "name": "Placebo tablet", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1202, "start_date": "2008-08", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2015-04-20", "last_synced_at": "2026-10-07T04:45:54.308Z", "location_count": 35, "location_summary": "Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 32 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Mission Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00734474" }, { "nct_id": "NCT05163223", "title": "Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "AST-301(pNGVL3-hICD)", "type": "BIOLOGICAL" }, { "name": "rhuGM-CSF", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Aston Sci. Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2022-02-28", "completion_date": "2024-05-31", "has_results": false, "last_update_posted_date": "2024-06-17", "last_synced_at": "2026-10-07T04:45:54.308Z", "location_count": 10, "location_summary": "Chandler, Arizona • La Jolla, California • Tampa, Florida + 7 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05163223" }, { "nct_id": "NCT02948959", "title": "Evaluation of Dupilumab in Children With Uncontrolled Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Asthma Controller Therapies", "type": "DRUG" }, { "name": "Asthma Reliever Therapies", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "6 Years to 11 Years" }, "enrollment_count": 408, "start_date": "2017-04-21", "completion_date": "2020-08-26", "has_results": true, "last_update_posted_date": "2022-03-28", "last_synced_at": "2026-10-07T04:45:54.308Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Rolling Hills Estates", "state": "California" }, { "city": "Owensboro", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT02948959" }, { "nct_id": "NCT03472378", "title": "Can DFN-15 Terminate Migraine With Allodynia?", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Migraine With Aura", "Migraine Without Aura", "Allodynia" ], "interventions": [ { "name": "DFN-15", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hartford Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 51, "start_date": "2018-05-09", "completion_date": "2019-04-12", "has_results": false, "last_update_posted_date": "2019-04-16", "last_synced_at": "2026-10-07T04:45:54.308Z", "location_count": 1, "location_summary": "West Hartford, Connecticut", "locations": [ { "city": "West Hartford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03472378" }, { "nct_id": "NCT01371578", "title": "Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "GS-5885 tablet", "type": "DRUG" }, { "name": "GS-9451 tablet", "type": "DRUG" }, { "name": "peginterferon alfa-2a", "type": "BIOLOGICAL" }, { "name": "ribavirin tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 163, "start_date": "2011-07", "completion_date": "2013-03", "has_results": false, "last_update_posted_date": "2014-02-11", "last_synced_at": "2026-10-07T04:45:54.308Z", "location_count": 54, "location_summary": "Dothan, Alabama • Montgomery, Alabama • Beverly Hills, California + 43 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01371578" }, { "nct_id": "NCT00605904", "title": "Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alcoholism" ], "interventions": [ { "name": "Acamprosate", "type": "DRUG" }, { "name": "Yohimbine", "type": "DRUG" }, { "name": "mCPP", "type": "DRUG" }, { "name": "Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 37, "start_date": "2008-01", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2012-07-03", "last_synced_at": "2026-10-07T04:45:54.308Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00605904" }, { "nct_id": "NCT01442532", "title": "A Study of the Safety and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Male Participants and the Effect of JNJ-38518168 on the Blood Levels of Midazolam", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Male Volunteer" ], "interventions": [ { "name": "JNJ-38518168 (30 mg)", "type": "DRUG" }, { "name": "JNJ-38518168 (10 mg)", "type": "DRUG" }, { "name": "JNJ-38518168 (3 mg)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Midazolam and JNJ-38518168", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 94, "start_date": "2011-09", "completion_date": "2012-07", "has_results": false, "last_update_posted_date": "2013-03-04", "last_synced_at": "2026-10-07T04:45:54.308Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01442532" } ] }